BofA cuts Abbott Labs stock price target on growth concerns By Investing.com

BofA cut Abbott Laboratories' price target to $120 from $150 while keeping a Buy rating, citing softer first-quarter performance in Libre, structural heart, and EXAS growth and lower implied organic growth needs for 2026. Abbott reported Q1 2026 adjusted EPS of $1.15 and revenue of $11.16 billion, both roughly in line to slightly above expectations, but guidance confidence remains muted as 2026 is framed as a transition year. Shares trade at $95.47, near the 52-week low of $93.92, with the stock down 23% year to date.

Analysis

The cut to Abbott’s target matters less for the headline and more for the reset in what has to go right. By moving the goalposts to a lower near-term organic growth bar, the market can tolerate weaker operational execution for longer, which usually compresses estimate revisions but also delays the valuation de-rating catalyst. The key second-order effect is that the stock can remain “cheap but not working” for several quarters if investors conclude 2026 is a bridge year rather than an inflection year.

The bigger risk is that this becomes a classic multiple trap: a high-quality defensive name with visible cash flow, but with several major growth legs underwhelming at the same time. If U.S. demand is soft while international is carrying the quarter, the market may start treating the business as a geography mix story rather than a durable compounder story, which typically caps rerating even on decent reported numbers. That makes any disappointment in the second-half acceleration disproportionately punitive, because the market is already anchoring to a future rebound rather than current fundamentals.

Consensus appears to be underestimating how long it can take for sentiment to recover once a franchise loses narrative momentum. The contrarian view is that the lower target could actually be constructive if it flushes out the last of the “perfection” expectations and resets the stock for a cleaner setup into 2027. But that only works if management can show a sequence of quarter-by-quarter stabilization; otherwise, the stock likely oscillates in a broad low-90s to low-100s range until the market gets hard evidence that growth has re-accelerated.

Key Decisions for Investors

• Avoid chasing ABT on strength; use rallies into the high-$90s / low-$100s to fade or trim exposure over the next 1-2 quarters unless channel checks show clear improvement in Libre and structural heart.
• Pair trade: long a higher-confidence large-cap medtech compounder vs short ABT for 3-6 months, expressing the view that Abbott’s rerating will lag peers until growth re-accelerates; target a 5-8% relative move if execution remains mixed.
• Sell ABT downside puts or put spreads only if willing to own the stock in the low-$90s; the implied floor is near recent lows, but fundamental support is not strong enough to justify aggressive premium collection below that level.
• Watch for a 2Q/3Q guide reset or commentary on second-half acceleration; if management confirms stabilization, consider a tactical long with a 6-9 month horizon toward the low-$110s, but only with a tight stop on any repeat organic-growth miss.